Page 2 - Zydus Pharmaceuticals

Zydus seeks DCGI nod for add'l indication of Hep C drug in Covid-19 therapy

In a likely breakthrough, interim results indicate that PegIFN when administered early on, could help patients recover faster and avoid complications seen in advanced Covid stages

November domestic pharma sales grow just 1% after strong show last month

Oct growth rate was 9.6%; Most big corporates saw volumes drop in November

Will focus on three-pronged strategy to drive growth: Zydus Wellness

The company is also planning to enter new markets with relevant offering as part of expanding its geographical footprint, Zydus Wellness said

Zydus Wellness board approves fund-raising of up to Rs 1,100 crore

As of quarter ended June 30, 2020, Zydus Family Trust held 4.29 per cent stake in Zydus Wellness

Zydus Cadila launches India's 'cheapest' remdesivir at Rs 2,800 per vial

Zydus is the fifth company to launch a copy of the antiviral in India after privately held Hetero Labs Ltd, Cipla, Mylan NV and Jubilant Life Sciences Ltd

Zydus Wellness June quarter net profit increases 11% at Rs 89 crore

Zydus group firm Zydus Wellness on Friday reported a 10.94 per cent rise in consolidated net profit at Rs 89.20 crore for the quarter ended June 30, 2020. The company had posted a net profit of Rs 80.40 crore for the corresponding period of the previous year,Zydus Wellness said in a filing to BSE. Consolidated revenue from operations of the company stood at Rs 537.37 crore for the quarter under consideration, as against Rs 620.25 crore in the year-ago period, it added. The past quarter was an "unprecedented one" due to the COVID-19 pandemic impacting the company's operations in the early part of the quarter, Zydus Wellness said. "However, with the logistical challenges being resolved and approvals for re-starting manufacturing plants and operating C&FA warehouses coming in, the company was able to recover from the early setbacks,"it added. Coping with the pandemic, the company continues to be agile in its responses and execution of its plans,Zydus Wellness said. Shares of Zydus .

Cadila Healthcare at the forefront, looks at biologic drug to treat Covid

Company is already working on developing 2 vaccine candidates, diagnostic kits and also making HCQ

Zydus Pharma gets USFDA nod to market attention-deficit hyperactivity drug

The final approval from the United States food and drug administration (USFDA) is to market Dextroamphetamine Saccharate

Zydus arm receives USFDA nod to market Omega-3-Acid Ethyl Esters capsules

Omega-3-acid ethyl esters, a type of fat found in fish oil, is used along with diet and exercise to help lower levels of a certain blood fat

Zydus gets final USFDA nod for anti-bacterial drug to treat acne, malaria

Zydus Cadila is a global pharmaceutical company that develops, manufactures and markets a broad range of healthcare therapies

Zydus Pharmaceuticals receives USFDA nod to market OCD treatment drug

Zydus Pharmaceuticals Inc is a wholly-owned subsidiary of Cadila Healthcare Ltd

Zydus gets US health regulator nod for hypertension drug Nifedipine

The company will produce the drug at the group's formulations manufacturing facility at SEZ, Ahmedabad.